Skip To Main Content
Sarah A Holstein on Muck Rack

Sarah A Holstein

Omaha
As seen in: Nature, Wiley Online Library, Drugs.com, The Lancet, ONCOLOGY journal, The ASCO Post, OncLive, Targeted Oncology, Patient Power
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sarah A

Contact Sarah A, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The role of the unfolded protein response pathway in bone homeostasis and potential therapeutic target in cancer-associated bone disease - Bone Research

|
By Molly E. Muehlebach, Sarah A Holstein
| Nature Verified
Abstract The unfolded protein response pathway is an evolutionarily conserved cytoprotective signaling cascade, essential for cell function and survival. Unfolded protein response signaling is tightly integrated with bone cell differentiation and function, and chronic unfolded protein response activation has been identified in bone disease.
Open in Who Shared Issue with article?

A Reflection on the Evolution of Antibody‐Based Therapies in Oncology: Trastuzumab as an Exemplar-Commentary on Dijkers et al.

|
By Sarah A Holstein
| Wiley Online Library Verified
Since the first description of hybridoma cells capable of producing monoclonal antibodies (mAbs) 50 years ago, remarkable progress has been made in the development of antibody-based therapies in oncology. Featured in this issue of CPT is an article first published in 2010 describing 89Zr-trastuzumab for immuno-positron emission tomography (PET) imaging.
Open in Who Shared Issue with article?

A Phase II Trial of Geriatric Assessment‐Guided Selection of Treatment Intensity in Older Adults With AML

|
By Vijaya R Bhatt, Christopher S Wichman, Thuy T. Koll, Alfred L. Fisher, Tanya M. Wildes, Michael Haddadin, Ann Berger, James Armitage, Sarah A Holstein, Krishna Gundabolu, Alfred L. Fisher, Lori J. Maness
| Wiley Online Library Verified
1 Introduction How to select appropriate intensity of chemotherapy in older adults with acute myeloid leukemia (AML) remains an unanswered question. While consensus-driven subjective criteria exist, prospectively validated objective criteria to determine fitness for intensive chemotherapy are lacking [1, 2].
Open in Who Shared Issue with article?
See all 24 licensed articles (32 Total)